DE60220400D1 - Verwendung von 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten - Google Patents

Verwendung von 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten

Info

Publication number
DE60220400D1
DE60220400D1 DE60220400T DE60220400T DE60220400D1 DE 60220400 D1 DE60220400 D1 DE 60220400D1 DE 60220400 T DE60220400 T DE 60220400T DE 60220400 T DE60220400 T DE 60220400T DE 60220400 D1 DE60220400 D1 DE 60220400D1
Authority
DE
Germany
Prior art keywords
alpha
alkyl
hydrogen
epoxyandrostan
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220400T
Other languages
English (en)
Other versions
DE60220400T9 (de
DE60220400T2 (de
DE60220400T3 (de
Inventor
Christopher Wood
George Margetts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stegram Pharmaceuticals Ltd
Original Assignee
Stegram Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9912534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60220400(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stegram Pharmaceuticals Ltd filed Critical Stegram Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60220400D1 publication Critical patent/DE60220400D1/de
Publication of DE60220400T2 publication Critical patent/DE60220400T2/de
Publication of DE60220400T3 publication Critical patent/DE60220400T3/de
Publication of DE60220400T9 publication Critical patent/DE60220400T9/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
DE60220400T 2001-04-09 2002-04-09 Verwendung von 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten Active DE60220400T9 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0108865 2001-04-09
GB0108865A GB2375958B (en) 2001-04-09 2001-04-09 The use of steroids to lower the levels of cortisol
EP02708546A EP1385527B2 (de) 2001-04-09 2002-04-09 Verwendung von 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten
PCT/GB2002/001653 WO2002080930A1 (en) 2001-04-09 2002-04-09 Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals

Publications (4)

Publication Number Publication Date
DE60220400D1 true DE60220400D1 (de) 2007-07-12
DE60220400T2 DE60220400T2 (de) 2008-01-31
DE60220400T3 DE60220400T3 (de) 2012-03-22
DE60220400T9 DE60220400T9 (de) 2012-08-30

Family

ID=9912534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220400T Active DE60220400T9 (de) 2001-04-09 2002-04-09 Verwendung von 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-on derivativen zur senkung des kortisolserumspiegels und zur behandlung von damit verbundenen krankheiten

Country Status (18)

Country Link
US (1) US9283235B2 (de)
EP (1) EP1385527B2 (de)
JP (1) JP5006502B2 (de)
AT (1) ATE363285T1 (de)
AU (1) AU2002242906B2 (de)
CA (1) CA2443633C (de)
CY (1) CY1106818T1 (de)
DE (1) DE60220400T9 (de)
DK (1) DK1385527T4 (de)
ES (1) ES2287252T5 (de)
GB (1) GB2375958B (de)
IL (2) IL158361A0 (de)
MX (1) MXPA03009236A (de)
NZ (1) NZ529141A (de)
PT (1) PT1385527E (de)
SI (1) SI1385527T2 (de)
WO (1) WO2002080930A1 (de)
ZA (1) ZA200308567B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
FR2931678B1 (fr) * 2008-05-27 2010-10-01 Cll Pharma Utilisation du trilistane pour le traitement de la depression
US9216221B2 (en) 2008-11-07 2015-12-22 University Of Sheffield Medicament and method of diagnosis for treating subclinical Cushing's syndrome
CA2765883A1 (en) * 2009-06-22 2010-12-29 Dmi Acquisition Corp. Methods and products for treatment of diseases
AU2010264524B2 (en) 2009-06-22 2015-03-19 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3296255A (en) * 1963-11-29 1967-01-03 Sterling Drug Inc 2-cyano steroids
GB1123770A (en) * 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US3296295A (en) * 1964-05-22 1967-01-03 Squibb & Sons Inc Norsteroids
US4029776A (en) * 1975-12-19 1977-06-14 Sterling Drug Inc. Therapeutic composition and method of use thereof
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4062954A (en) * 1976-12-27 1977-12-13 Sterling Drug Inc. Process for using a steroid compound
US4160027A (en) 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
US4331663A (en) 1981-06-19 1982-05-25 Sterling Drug Inc. 4α,5α-Epoxy-3,20-dioxopregnane-2α,16α-dicarbonitrile and intermediates and process for preparation, method of use and compositions thereof
ES8504486A1 (es) 1982-11-02 1985-05-01 Sterwin Ag Procedimiento de trituracion de compuestos esteroides
JPS5971578U (ja) * 1982-11-04 1984-05-15 アンプ　インコ−ポレ−テツド 電気コネクタ組立体
GB8328929D0 (en) 1983-10-29 1983-11-30 Sterwin Ag Steroid compounds
GB2155018B (en) * 1984-02-25 1988-04-07 Sterwin Ag 2x-cyano-4d,5x-epoxy-androstane -3,17-dione
GB8404980D0 (en) * 1984-02-25 1984-03-28 Sterwin Ag Steroid compound
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4755595A (en) * 1985-11-01 1988-07-05 Sterling Drug Inc. Enhanced production of 4,5-unsaturated steroids utilizing methanol solvation
US5795881A (en) * 1987-06-16 1998-08-18 Schering Aktiengesellschaft Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
US4857333A (en) * 1988-05-12 1989-08-15 Harold Robert G Food product for administering medication to animals
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
GB2345851B (en) * 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
JP2003533490A (ja) 2000-05-15 2003-11-11 フアルマシア・イタリア・エツセ・ピー・アー 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors

Also Published As

Publication number Publication date
DE60220400T9 (de) 2012-08-30
DE60220400T2 (de) 2008-01-31
US20040204392A1 (en) 2004-10-14
EP1385527B1 (de) 2007-05-30
CA2443633A1 (en) 2002-10-17
PT1385527E (pt) 2007-08-21
GB0108865D0 (en) 2001-05-30
MXPA03009236A (es) 2004-11-12
GB2375958A (en) 2002-12-04
EP1385527B2 (de) 2011-11-23
JP5006502B2 (ja) 2012-08-22
IL158361A (en) 2013-07-31
NZ529141A (en) 2005-09-30
DE60220400T3 (de) 2012-03-22
DK1385527T3 (da) 2007-10-29
CA2443633C (en) 2010-06-22
WO2002080930A1 (en) 2002-10-17
AU2002242906B2 (en) 2009-07-02
US9283235B2 (en) 2016-03-15
DK1385527T4 (da) 2012-01-16
ZA200308567B (en) 2006-04-29
ES2287252T3 (es) 2007-12-16
ATE363285T1 (de) 2007-06-15
GB2375958B (en) 2005-03-02
SI1385527T2 (sl) 2012-03-30
CY1106818T1 (el) 2012-05-23
IL158361A0 (en) 2004-05-12
JP2004529142A (ja) 2004-09-24
ES2287252T5 (es) 2012-03-26
EP1385527A1 (de) 2004-02-04
SI1385527T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
CY1106818T1 (el) Χρηση παραγωγων 2-αλφα-κυανο-4-αλφα, 5-αλφα-εποξυανδροσταν-17-βητα -ολ-3-ονης για μειωση επιπεδων κορτιζολης ορου και για τη θεραπεια κλινικων καταστασεων που σχετιζονται με αυτη
DE60129550D1 (de) Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
RU93058524A (ru) Системы с регулируемым высвобождением и низкими дозами андрогенов, способ их получения и способ лечения с помощью этих систем
EE05025B1 (et) Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
ATE350041T1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
ID26781A (id) Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer
ATE439845T1 (de) Kombination von einem ístrogen und einem androgen zur behandlung von hormonmangel in der ístrogenersatztherapie für frauen
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
DE69413829T2 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
ATE468109T1 (de) Liposomale abgabe von verbindungen auf vitamin-e- basis
ES2078890T3 (es) Amino esteroides en c20 a c26.
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
HUP0401687A2 (hu) Szteroid-szulfatáz inhibitor acil-szulfonamidok és ezeket tartalmazó gyógyszerkészítmények
ATE358489T1 (de) Verwendung von 7alpha-hydroxy-estradiol, 7alpha- hydroxy-dehydroepiandrosteron and 7alpha-hydroxy- pregnenolon derivaten zur behandlung der akuten zellulären degeneration
DE69230069T2 (de) Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms
CA2395481A1 (en) Hormone receptor modulation
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
DE60002692D1 (de) Leberspezifische gallensaeurederivate des antiglukokorticoids ru486
DE60132436D1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
WO2004093852A3 (en) Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
DE60228431D1 (de) Heilmittel für erkrankungen der retina und der aderhaut die als aktive bestandteile steroide enthalten
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1385527

Country of ref document: EP

Effective date: 20111123